COMMUNICATION IS CRITICAL
Evidence suggests that breakdowns in the bowel-brain communication pathway are the root cause of chronic fecal incontinence (FI).1 While more conservative therapies focus on the bowel and related muscles, Medtronic bowel control therapy targets the nerves, which is thought to help restore normal bowel function.*
THE RELIEF YOU’VE BEEN WAITING FOR
When more conservative treatments fail, Medtronic Bowel Control Therapy delivered by the InterStim™ systems can help. This therapy is simple and discreet, and it delivers the kind of relief that lets you enjoy the activities you love without a second thought.
THE CHOICE IS YOURS
Medtronic bowel control therapy delivered by the InterStim™ systems offers recharge-free and rechargeable options, so you can choose the right one for your lifestyle.
Compare the InterStim™ II and InterStim™ Micro systems for bowel control.
Implanting an InterStim™ system has risks similar to any surgical procedure, including swelling, bruising, bleeding, and infection. Talk with your doctor about ways to minimize these risks.
Medtronic bowel control therapy delivered by the InterStim™ II system provides life-changing relief. And the InterStim™ Micro system is designed to deliver the same effective results.
The most common adverse events experienced during clinical studies included pain at implant sites, new pain, lead migration, infection, technical or device problems, adverse change in bowel or voiding function, and undesirable stimulation or sensations. Any of these may require additional surgery or cause return of symptoms.
Defined as 50% or greater reduction in chronic fecal incontinence episodes.
Data from InterStim Sales Analysis. Medtronic, Inc. December 2019.
Under certain conditions. See approved labeling for details. Patients with InterStim™ SureScan MRI leads only.
Battery life may vary based on therapy settings.
Under standard patient therapy settings and appropriate recharger placement.
Success defined as ≥ 50% reduction of episodes/week. This patient group had data at both baseline and the 5 year visit. Another analysis reported 69% of people achieved success with Medtronic Bowel Control Therapy. For this patient group, missing data at 5 years because of a device-related reason was counted as failure or if it was missing for non-device related reasons, the most recent data was carried forward.
Patton V, Wiklendt L, et al. The effect of sacral nerve stimulation on distal colonic motility in patients with fecal incontinence. Br J Surg. 2013 Jun;100(7):959-68.
National Association for Continence. Bowel Health. nafc.org/bowel-incontinence. Accessed June 26, 2017.
Hull T, Giese C, Wexner SD, et al. Long-term Durability of Sacral Nerve Stimulation Therapy for Chronic Fecal Incontinence. Dis Colon Rectum. 2013; 56(2):234-45.
Information on this site should not be used as a substitute for talking with your doctor. Always talk with your doctor about diagnosis and treatment information.